imatinib mesylate has been researched along with Anemia, Aplastic in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ben Said, F; Elloumi, M; Kallel, F; Kassar, O; Khabir, A; Ksouda, K; Mallek, R | 1 |
| Amat, P; Collado, M; Hernández-Boluda, JC; Marugán, I; Roda, D; Tormo, M | 1 |
| Damnhouri, G; Elhefni, AM; Mabed, M | 1 |
| Chng, WJ; Tan, LH | 1 |
| Hoyer, R; Krook, J; LeMarbre, G; Schinstock, C; Tefferi, A | 1 |
| Kumar, R; Pati, HP; Pillai, LS; Saxena, R; Srinivas, U | 1 |
| Azzarà, A; Buda, G; Carulli, G; Cervetti, G; Galimberti, S; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
7 other study(ies) available for imatinib mesylate and Anemia, Aplastic
| Article | Year |
|---|---|
Aplastic anemia secondary to tyrosine kinase inhibitor therapy in a patient with chronic myeloid leukemia.
Topics: Adult; Anemia, Aplastic; Bone Marrow; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia.
Topics: Aged; Analgesics, Non-Narcotic; Anemia, Aplastic; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Benzamides; Cyclosporine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mycoses; Piperazines; Pyrimidines; Remission Induction; Respiratory Tract Infections | 2009 |
Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.
Topics: Anemia, Aplastic; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2012 |
Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia.
Topics: Anemia, Aplastic; Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Male; Middle Aged; Pancytopenia; Piperazines; Pyrimidines; Singapore; Time Factors | 2005 |
Late onset aplastic anemia during treatment of chronic myeloid leukemia with imatinib mesylate.
Topics: Anemia, Aplastic; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunoglobulins; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Prednisone; Pyrimidines; Time Factors; Treatment Outcome | 2007 |
Bone marrow aplasia--a rare complication of imatinib therapy in CML patients.
Topics: Adolescent; Adult; Anemia, Aplastic; Benzamides; Blast Crisis; Bone Marrow Examination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pancytopenia; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia.
Topics: Adult; Anemia, Aplastic; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2008 |